Skip to content

Clinical observation of oxycodone combined with flurbiprofen ester undergoing transforaminal lumbar interbody fusion surgery in patient intravenous controlled analgesia:a randomized, controlled, double-blind, trial

Clinical observation of oxycodone combined with flurbiprofen ester undergoing transforaminal lumbar interbody fusion surgery in patient intravenous controlled analgesia:a randomized, controlled, double-blind, trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020721
Enrollment
Unknown
Registered
2019-01-15
Start date
2019-02-01
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative analgesia

Interventions

group O:oxycodone combined with flurbiprofen ester
Group M:Morphine compound flurbiprofen ester

Sponsors

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) selective transforaminal lumbar interbody fusion; 2) Postoperative patient-controlled intravenous analgesia; 3) aged 40-75 years old; 4) BMI <28kg/m2; 5) ASA I or II; 6) Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe impairment of Heart, Lung, brain, liver and Kidney function; 2. Intracranial hypertension, severe hypertension (grade III and above) and systolic blood pressure (SBP) > 180mmhg or diastolic blood pressure (DBP) > 110mmhg were not decreased twice in a row; 3. Gastrointestinal bleeding or peptic ulcer; 4. Aspirin asthma or previous history; 5. Allergy to the drugs used in this subject; 6. Long-term preoperative administration of opiates, sedative and analgesic drugs, psychoactive drugs; 7. Taking Elofloxacin, Lomefloxacin, Norfloxacin; 8. Suffering from mental, neuromuscular diseases; 9. Unable to express will correctly, unable to give verbal guidance and cooperation; 10. Hypothyroidism / cortical insufficiency; 11. Prostatic hypertrophy, dysuria.

Design outcomes

Primary

MeasureTime frame
VAS score;cumulative dosage of analgesic pump;Effective pressing / total pressing;Remedial analgesic dosage;

Secondary

MeasureTime frame
Number of bowel sounds;Abdominal distension rate;Postoperative first exhaust time;Other side effects;Postoperative recovery (first turn over, walk time);

Countries

China

Contacts

Public ContactBin Ji

The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

wzmcjb@163.com+86 13868441466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026